Vascular Endothelial Growth Factor Expression in Invasive Papillary Thyroid Carcinoma

Thyroid ◽  
2009 ◽  
Vol 19 (11) ◽  
pp. 1233-1237 ◽  
Author(s):  
Vergilius José Furtado de Araujo-Filho ◽  
Venancio Avancini Ferreira Alves ◽  
Ines Vieira de Castro ◽  
Silvia Vanessa Lourenço ◽  
Claudio Roberto Cernea ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Vascular Endothelial ◽  
Papillary Thyroid ◽  
Factor Expression ◽  
Growth Factor Expression ◽  
Endothelial Growth Factor

scholarly journals Interleukin-17 and vascular endothelial growth factor: new biomarkers for the diagnosis of papillary thyroid carcinoma in patients with Hashimoto’s thyroiditis

2022 ◽  
Vol 50 (1) ◽  
pp. 030006052110671
Author(s):  
Shuiping Li ◽  
Shilin Li ◽  
Min Lin ◽  
Zuolin Li ◽  
Jinghua He ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Hashimoto's Thyroiditis ◽  
Interleukin 17 ◽  
Vascular Endothelial ◽  
Papillary Thyroid ◽  
Increasing Trends ◽  
Endothelial Growth Factor

Objective The incidences of papillary thyroid carcinoma (PTC) and Hashimoto’s thyroiditis (HT) have shown increasing trends. Numerous studies have shown a close relationship between the two diseases, but the exact mechanism linking PTC with HT is still unclear. Interleukin-17 (IL-17) plays an important role in the development of malignant tumors. However, information on the association between IL-17 and thyroid disease is lacking. Methods Tissue samples were collected from patients with thyroid diseases admitted to the thyroid surgery department of our hospital between May 2015 and December 2017. The characteristics of the thyroid were observed by ultrasonography, hematoxylin-eosin staining, enzyme-linked immunosorbent assays, and immunohistochemistry. Results We found that HT with carcinoma (HTC) showed unique characteristics in two-dimensional ultrasound images. Moreover, IL-17 and vascular endothelial growth factor (VEGF) levels showed gradually increasing trends during the process of HT malignant transformation, with a significant positive correlation between the two cytokines. Serum IL-17 and VEGF levels could distinguish between HTC and HT with benign adenoma. Conclusion Our data suggest that serum IL-17 and VEGF levels may represent novel biomarkers for the diagnosis of HT malignant nodules.

Sign in / Sign up

Export Citation Format

Share Document